Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons JM van den Eertwegh, Winald R. Gerritsen, R. Jeroen A. van Moorselaar et al.|The Lancet Oncology|2012Cited by 357
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapyAurélie Hanoteau, Andrew G. Sikora, Jared M. Newton et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 89